IP Library › Granted Patent US 7,348,314
Granted Patent B2
US 7,348,314 · App. 10/384,512 · Granted Mar 25, 2008

Compositions and methods for inhibiting viral replication

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,348,314
App. No.
10/384,512
Granted
Mar 25, 2008
Kind
B2
Abstract

The present invention relates to a double-stranded ribonucleic acid (dsRNA) having a nucleotide sequence which is less that 30 nucleotides in length and which is substantially identical to at least a part of a 3′-untranslated region (3′-UTR) of a (+) strand RNA virus, such as HCV, as well as pharmaceutical compositions comprising the dsRNA, together with a pharmaceutically acceptable carrier. The pharmaceutical compositions are useful for treating infections and diseases caused by the replication or activity of the (+) strand RNA virus, as well as methods for inhibiting viral replication.

Claims (3)

1. A method for inhibiting the replication of hepatitis C virus in a hepatitis C virus infected cell in vitro, which comprises introducing a double-stranded ribonucleic acid (dsRNA) into the cell, wherein the dsRNA comprises a sense RNA strand consisting of SEQ ID No. 4 and an antisense strand consisting of SEQ ID NO:5.

2. The method of claim 1 , wherein the cell is a mammalian cell.

3. The method of claim 2 , wherein the mammalian cell is a human cell.

Assignments (1)
SECURITY INTEREST Recorded Oct 1, 2025
From: ALNYLAM PHARMACEUTICALS, INC.; SIRNA THERAPEUTICS, INC.
To: BANK OF AMERICA, N.A.
Reel/Frame 072996/0337 →